Subcellular specificity of cannabinoid effects in striatonigral circuits.

Animals Brain / drug effects Cannabinoid Receptor Agonists / pharmacology Cannabinoid Receptor Antagonists / pharmacology Catalepsy / chemically induced Cell Membrane / metabolism HEK293 Cells HeLa Cells Humans Male Mice Mice, Inbred C57BL Mitochondria / metabolism Nociception / drug effects Receptor, Cannabinoid, CB1 / metabolism Signal Transduction / drug effects Synaptic Transmission / drug effects
CB(1) receptor PKA THC antinociception catalepsy mitochondria substance P substantia nigra

Journal

Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320

Informations de publication

Date de publication:
05 05 2021
Historique:
received: 07 08 2020
revised: 09 02 2021
accepted: 04 03 2021
pubmed: 27 3 2021
medline: 12 6 2021
entrez: 26 3 2021
Statut: ppublish

Résumé

Recent advances in neuroscience have positioned brain circuits as key units in controlling behavior, implying that their positive or negative modulation necessarily leads to specific behavioral outcomes. However, emerging evidence suggests that the activation or inhibition of specific brain circuits can actually produce multimodal behavioral outcomes. This study shows that activation of a receptor at different subcellular locations in the same neuronal circuit can determine distinct behaviors. Pharmacological activation of type 1 cannabinoid (CB

Identifiants

DOI: 10.1016/j.neuron.2021.03.007 PMID: 33770505
pubmed: 33770505
pii: S0896-6273(21)00155-0
doi: 10.1016/j.neuron.2021.03.007
pii:
doi:

Substances chimiques

Cannabinoid Receptor Agonists 0
Cannabinoid Receptor Antagonists 0
Cnr1 protein, rat 0
Receptor, Cannabinoid, CB1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1513-1526.e11

Subventions

Organisme : CIHR
ID : 156238
Pays : Canada

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Edgar Soria-Gomez (E)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. Electronic address: edgar.soria@achucarro.org.

Antonio C Pagano Zottola (AC)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Yamuna Mariani (Y)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Tifany Desprez (T)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Massimo Barresi (M)

University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.

Itziar Bonilla-Del Río (I)

Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain.

Carolina Muguruza (C)

Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.

Morgane Le Bon-Jego (M)

University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.

Francisca Julio-Kalajzić (F)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Robyn Flynn (R)

Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.

Geoffrey Terral (G)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Ignacio Fernández-Moncada (I)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Laurie M Robin (LM)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

José F Oliveira da Cruz (JF)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Simone Corinti (S)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Yasmine Ould Amer (YO)

Canada Research Chair in Mitochondrial Signaling and Physiopathology, Department of Biology, University of Moncton, Moncton, NB, Canada.

Julia Goncalves (J)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Marjorie Varilh (M)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Astrid Cannich (A)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Bastien Redon (B)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Zhe Zhao (Z)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Thierry Lesté-Lasserre (T)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Peggy Vincent (P)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Tarson Tolentino-Cortes (T)

Department of Research and Development, IMG Pharma Biotech S.L., Derio, Spain.

Arnau Busquets-García (A)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Nagore Puente (N)

Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain.

Jaideep S Bains (JS)

Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.

Etienne Hebert-Chatelain (E)

Canada Research Chair in Mitochondrial Signaling and Physiopathology, Department of Biology, University of Moncton, Moncton, NB, Canada.

Gabriel Barreda-Gómez (G)

Department of Research and Development, IMG Pharma Biotech S.L., Derio, Spain.

Francis Chaouloff (F)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.

Alexander W Lohman (AW)

Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.

Luis F Callado (LF)

Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Pedro Grandes (P)

Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain; Division of Medical Sciences, University of Victoria, Victoria, BC, Canada.

Jerome Baufreton (J)

University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.

Giovanni Marsicano (G)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France. Electronic address: giovanni.marsicano@inserm.fr.

Luigi Bellocchio (L)

INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France. Electronic address: luigi.bellocchio@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Modulateurs des récepteurs de cannabinoïdes › Agonistes des récepteurs de cannabinoïdes › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Modulateurs des récepteurs de cannabinoïdes › Antagonistes des récepteurs de cannabinoïdes › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Dyskinésies › Catalepsie › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Cellules › Structures cellulaires › Membrane cellulaire › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HeLa › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Cellules › Structures cellulaires › Fractions subcellulaires › Mitochondries › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Perception › Perception de la douleur › Nociception › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB1 › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Subcellular specificity of cannabinoid effects...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Transmission synaptique › Subcellular specificity of cannabinoid effects...